Massachusetts General Hospital in Boston is expected to announce a $30 million partnership with Johnson & Johnson today to develop and market a noninvasive test that detects subtle traces of cancer cells in blood samples, according to a Boston Globe report.
The goal of the five-year partnership would be to commercialize the test, which would allow physicians to track and treat cancer more efficiently. An official from the MGH Cancer Center said the hospital wants to standardize the test and technology, making it easy to use and available on a global scale, according to the report.
The promising test has seen other funding in the cancer community, as well. The organization Stand Up to Cancer gave researchers a $15 million grant to test the prototype of a microchip that can detect tumor cells at extremely low levels in the bloodstream.
Read the Boston Globe report on Massachusetts General Hospital's partnership with Johnson & Johnson for cancer testing.
Read more about Massachusetts General Hospital:
- A $1.5B Campaign: Mass General’s VP for Development on the Hospital’s Ambitious Fundraising Initiative
- Hospital Leader to Know: Dr. Peter Slavin, CEO of Massachusetts General Hospital
- 30 Hospitals With Great Oncology Programs
The goal of the five-year partnership would be to commercialize the test, which would allow physicians to track and treat cancer more efficiently. An official from the MGH Cancer Center said the hospital wants to standardize the test and technology, making it easy to use and available on a global scale, according to the report.
The promising test has seen other funding in the cancer community, as well. The organization Stand Up to Cancer gave researchers a $15 million grant to test the prototype of a microchip that can detect tumor cells at extremely low levels in the bloodstream.
Read the Boston Globe report on Massachusetts General Hospital's partnership with Johnson & Johnson for cancer testing.
Read more about Massachusetts General Hospital:
- A $1.5B Campaign: Mass General’s VP for Development on the Hospital’s Ambitious Fundraising Initiative
- Hospital Leader to Know: Dr. Peter Slavin, CEO of Massachusetts General Hospital
- 30 Hospitals With Great Oncology Programs